Author,year | Model | Country | Intervention | Validation type | Sample size(N) | Outcome | Predictors | AUC (95%CI) | Discrimination plot | Calibration plot |
---|---|---|---|---|---|---|---|---|---|---|
Adhoute X, 2016 [33] | NIACE | France | Surgery, TACE, Sorafenib | IV,EV | 161 | OS | the number of nodules, the infiltrating nature of the HCC, AFP, CP, ECOG PS | 0.784 | Absent | Absent |
Berhane S, 2019 [17] | PROSASH | UK | sorafenib | IV | 588 | OS | vascular invasion, age, ECOG PS, AFP, albumin, creatinine, AST, extra hepatic spread and aetiology | 0.72 to 0.70 | Absent | Present |
Chan SL, 2019 [34] | ILIS | Hong Kong Newcastle | sorafenib | IV,EV | 627 | OS | albumin, Bilirubin, alkaline phosphatase, Neutrophil, AFP | / | Absent | Absent |
Choi GH, 2014 [35] | SPSM | US | sorafenib | IV,EV | 356 | OS | CP, AFP, tumor morphology, vascular invasion, extrahepatic involvement | 0.809 (0.765–0.868) | Present | Present |
Conroy G, 2017 [36] | IBSs-SII | France | sorafenib | / | 161 | OS | AST, BMI, SII, CP-B, macroscopic vascular invasion | / | Absent | Absent |
Di Costanzo GG,2015 [37] | 3-GPI | Italy | sorafenib | IV,EV | 226 | OS | AFP, bilirubin, ALT | / | Absent | Absent |
Di Costanzo GG, 2017 [38] | OTE | Italy | sorafenib | IV | 279 | OS | Skin toxicity, diarrhoea, arterial hypertension | 0.715 (0.645–0.785) | Present | Absent |
Diaz-Beveridge R, 2017 [39] | La Fa | Spain | sorafenib | IV | 145 | OS | ECOG PS, CP score, early onset diarrhoea, bNLR | 0.69 | Absent | Absent |
Edeline J, 2017 [40] | SAP | France, UK | sorafenib | IV,EV | 370 | OS | ECOG PS, AFP, tumour size, bilirubin, albumin | 0.732 (0.669–0.789) | Absent | Absent |
Ha Y, 2020 [41] | LMR-N | Korea, US | sorafenib | / | 297 | OS | LMR, treatment location, previous treatment, PS, AFP, lymph node metastasis, CP score | 0.71 (0.67–0.75) | Absent | Absent |
Howell J, 2017 [42] | RD-CLIP | Japan, Italy and UK | sorafenib | / | 442 | OS | CLIP score, RDW, treatment-related diarrhoea | 0.808 (0.734–0.882) | Absent | Absent |
Kim HY,2018 [43] | NBBM | Korea | sorafenib | IV | 124 | OS | etiology, platelet count, BCLC, PIVKA- II, HGF, FGF | 0.825 (0.734–0.915) | Present | Absent |
Kinoshita A,2013 [44] | GPS | Japan | TACE, TAI, systemic chemotherapy, sorafenib or BSC | / | 150 | OS | AST, total bilirubin, decreased albumin, AFP, larger tumor diameter, tumor number, vascular invasion, extra hepatic metastasis, CP, CLIP | 0.897 (0.699–0.876) | Present | Absent |
Labeur TA,2020 [18] | PROSASH-II | Bordeaux, France, Germany, Amsterdam, Rotterdam | sorafenib | IV,EV | 615 | OS | the serum albumin, bilirubin, AFP, macrovascular invasion, extrahepatic spread, largest tumour size | 0.63 (0.60–0.66) | Absent | Absent |
Lee HW,2017 [45] | NEXT | Korea | sorafenib | IV,EV | 272 | OS | ECOG PS, CP score, serum sodium, AFP | 0.809 (0.758–0.860) | Present | Absent |
Nakanishi H,2016 [46] | BCP | Japan | sorafenib | / | 165 | OS | CRP, albumin, AFP, lack of major vascular invasion | / | Absent | Absent |
Pan QZ,2015 [47] | ACIKCI-N | China | adjuvant CIK cell immunotherapy | IV | 1031 | OS | tumor size, tumor capsule, pathological grades, total bilirubin, albumin, PT, AFP, tumor number | 0.698 (0.677–0.719) | Present | Present |
Qin S,2017 [48] | FOLFOX4-N | mainland China, Taiwan, Korea, and Thailand | FOLFOX 4 | IV | 184 | OS | age, maximum tumor diameter, lymph node status, AST, TBIL, AFP | 0.75 (0.71–0.80) | Absent | Present |
Sprinzl MF,2018 [49] | GPS-EP | Germany | sorafenib | IV | 120 | OS | ECOG PS, PVTT, GPS | 0.826 (0.746–0.907) | Present | Absent |
Takeda H,2015 [19] | JRC | Japan | sorafenib | IV | 270 | OS | distant metastases, PVTT, intrahepatic tumor burden, AFP, des-γ-carboxyprothrombin, albumin, total bilirubin | 0.755 (0.707–0.803) | Absent | Absent |
Tang C,2020 [50] | 9-MRG | ①TCGA②ICGC | sorafenib | EV | 374 | OS | RRM2, DTYMK, LPCAT1, LCAT, TXNRD1, G6PD, PTGES, ENTPD2, UCK2 | 0.797 | Present | Present |
Yoo JJ,2017 [20] | SCHCC | Korea | sorafenib | IV | 612 | OS | CP, AFP, tumor type, extrahepatic metastasis, PVTT | 0.818 | Absent | Absent |
Yuan J,2017 [51] | PBNC-N | China | sorafenib | / | 464 | OS | HBsAg, neutrophil count, thrombus, metastasis, tumor size | 0.79 | Present | Present |
Liu T,2020 [52] | 7-IRGBM | TCGA, ICGC | / | IV,EV | 374 | OS | BIRC5, FOS, DKK1, FGF13, IL11, IL17D, SPP1 | 0.778 | Present | Absent |
Huo J,2020 [53] | IGPPM | TCGA, ICGC | / | IV,EV | 374 | OS | 45 immune-gene pairs with general applicability | 0.899 | Present | Absent |
Xu D,2020 [54] | 8-IPSHCC | TCGA, ICGC | / | IV,EV | 423 | OS | CKLF, IL12A, CCL20, PRELID1, FYN, GLMN, ACVR2A, CD7 | 0.79 | Present | Absent |
Wang WJ,2020 [55] | 10-IRGPM | China, TCGA | / | IV,EV | 374 | OS | BIRC5, CSPG5, IL-11, FABP6, FIGNL2, GAL, IL17D, MAPT, SPP1, STC2 | 0.818 | Present | Absent |
Wang Z,2020 [56] | 9-NIRPM | TCGA,ICGC | / | IV,EV | 337 | OS | ANGPT1, MAPT, DCK, SEMA3F, IL17D, HSPA4, RBP2, NDRG1, OSGIN1 | 0.811 | Present | Absent |